Lisocabtagene maraleucel
- Generic Name:
- Lisocabtagene maraleucel
- Drug Type:
- CD19-directed genetically modified autologous T cell immunotherapy
- How the Drug is Given:
Intravenously (IV)
- Names:
- Breyanzi®
- Lisocabtagene maraleucel
Indications and Usage
Lisocabtagene maraleucel is indicated for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
- refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
- refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
- relapsed or refractory disease after two or more lines of systemic therapy.
Limitations of Use: Lisocabtagene maraleucel is not indicated for the treatment of patients with primary central nervous system lymphoma.
Side effects needing medical attention
The most common adverse reactions in Breyanzi-treated patients were fatigue, cytokine release syndrome, musculoskeletal pain, nausea, headache, encephalopathy (damage or disease that affects the brain) , infections, decreased appetite, diarrhea, low blood pressure (hypotension), tachycardia (heart rate over 100 beats per minute), dizziness, cough, constipation, abdominal pain, vomiting, and edema (swelling).